Insulin, Neurogenetics and Memory in Alzheimer's Disease

US Department of Veterans Affairs

Overview

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Sex: ALLMin age: 55 YearsMax age: 80 Years

Medical Language ↔ Plain English

Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.

VA Puget Sound Health Care System

Seattle, Washington, United States

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.